Back to top
more

Provectus Biopharmaceuticals (PVCT)

(Delayed Data from OTC)

$0.11 USD

0.11
50,000

0.00 (-3.18%)

Updated Jul 30, 2024 11:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Provectus Biopharmaceuticals, Inc. [PVCT]

Reports for Purchase

Showing records 1 - 20 ( 56 total )

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

05/22/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/22/2013

Company Report

Pages: 4

We are dropping coverage due to the departure of covering analyst.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

05/13/2013

Company Report

Pages: 4

We are suspending coverage in order to focus on other areas of interest to our institutional clients.

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/26/2012

Company Report

Pages: 8

Q3FY12 Update

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 25.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

10/09/2012

Company Report

Pages: 2

Transferring Coverage.

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/15/2012

Company Report

Pages: 3

Released FY2Q12 Financial Results

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/15/2012

Daily Note

Pages: 3

Released FY2Q12 Financial Results

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

07/24/2012

Daily Note

Pages: 19

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

07/23/2012

Company Report

Pages: 11

Re-cap of Positive PV-10 in Melanoma Phase II Results and KOL Comments

Provider: Roth Capital Partners, Inc.

Analyst: JEN Y

Price: 25.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

06/29/2012

Company Report

Pages: 3

We are placing Provectus Pharmaceuticals under review due to the departure from the firm of covering analyst

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

06/26/2012

Daily Note

Pages: 3

Phase 2 Positive Results in Melanoma

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

06/26/2012

Daily Note

Pages: 4

Phase 2 Positive Results in Melanoma

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/20/2012

Industry Report

Pages: 4

MONTHLY PORTFOLIO UPDATE

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/17/2012

Company Report

Pages: 8

Research Update: PVCT: Q112 Results and Top Line Phase II Data for PH 10

Provider: STONEGATE CAPITAL MARKETS

Analyst: ENGEL L

Price: 25.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

04/16/2012

Daily Note

Pages: 7

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

04/16/2012

Company Report

Pages: 4

Increased Awareness of Intralesional Therapy Bodes Well for PV-10 Outlook

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

04/12/2012

Daily Note

Pages: 10

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

04/11/2012

Company Report

Pages: 21

Robust results from PV-10 in melanoma trial support promising outlook

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/26/2012

Daily Note

Pages: 3

Animal Data Show Tumor Regression with PV-10

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Provectus Biopharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/26/2012

Company Report

Pages: 4

Animal Data Show Tumor Regression with PV-10

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party
// eof